GWM
PRME icon

Greenwich Wealth Management’s Prime Medicine PRME Stock Holding History

Greenwich Wealth Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Buy
768,001
+18,000
+2% +$59.8K 0.1% 99
2026
Q1 		$2.61M Buy
750,001
+10,000
+1% +$38.1K 0.11% 103
2025
Q4 		$2.57M Buy
740,001
+20,000
+3% +$89K 0.11% 103
2025
Q3 		$3.99M Sell
720,001
-126,200
-15% -$513K 0.2% 66
2025
Q2 		$2.09M Buy
846,201
+27,200
+3% +$41.9K 0.1% 90
2025
Q1 		$1.63M Buy
819,001
+45,000
+6% +$115K 0.12% 91
2024
Q4 		$2.26M Buy
774,001
+41,000
+6% +$144K 0.16% 73
2024
Q3 		$2.84M Buy
733,001
+80,000
+12% +$371K 0.19% 62
2024
Q2 		$3.36M Buy
653,001
+75,000
+13% +$455K 0.25% 49
2024
Q1 		$4.05M Buy
578,001
+65,000
+13% +$493K 0.32% 44
2023
Q4 		$4.54M Buy
513,001
+73,980
+17% +$570K 0.45% 35
2023
Q3 		$4.19M Buy
439,021
+231,021
+111% +$3M 0.44% 34
2023
Q2 		$3.05M Sell
208,000
-141,000
-40% -$1.97M 0.32% 52
2023
Q1 		$4.29M Buy
+349,000
New +$5.69M 0.47% 32

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Greenwich Wealth Management's PRME Position: Q2 2026 in Review

Greenwich Wealth Management increased its Prime Medicine (PRME) stake by 2.4% in Q2 2026, buying an estimated $59.8K and bringing the position to 768,001 shares worth $2.83M. The position accounts for 0.1% of the portfolio, ranked #99.

Greenwich Wealth Management first reported a position in PRME in Q1 2023 and has held it in 14 quarters since. The position peaked at $4.54M in Q4 2023. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Greenwich Wealth Management held 768,001 shares of Prime Medicine worth $2.83M as of Q2 2026.
  • Greenwich Wealth Management bought 18,000 Prime Medicine shares in Q2 2026, an estimated $59.8K.
  • Prime Medicine made up 0.1% of Greenwich Wealth Management's portfolio in Q2 2026, its #99 holding.
  • Greenwich Wealth Management first reported a position in Prime Medicine in Q1 2023 and has held it in 14 quarters since.
  • Greenwich Wealth Management's Prime Medicine position peaked at $4.54M in Q4 2023.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Greenwich Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.